Cisplatin-Ineligibility Flag for Pre-Surgery Bladder Cancer Referral
A tool that flags bladder cancer patients who cannot take a specific chemotherapy drug so they get referred to a specialist sooner.
An EHR-embedded triage tool that screens every new muscle-invasive bladder cancer diagnosis for cisplatin ineligibility (renal function, hearing, neuropathy, performance status) and automatically refers flagged patients to medical oncology before cystectomy is scheduled — capturing the neoadjuvant window where the new enfortumab vedotin + pembrolizumab benefit was demonstrated.
Concept
An EHR-embedded triage tool for urology clinics that runs at the moment muscle-invasive bladder cancer is diagnosed. It screens labs, audiometry, problem lists, and performance-status data against standard cisplatin-ineligibility criteria (reduced creatinine clearance, grade 2 or higher hearing loss, grade 2 or higher peripheral neuropathy, poor performance status, significant heart failure), flags cisplatin-ineligible patients, and generates a same-week medical oncology referral with a patient-facing explainer — before the surgeon books the cystectomy. The point is timing: the survival benefit demonstrated in [0] comes from starting enfortumab vedotin plus pembrolizumab before surgery (cystectomy after 3 cycles), a window that is lost the moment a cisplatin-ineligible patient is scheduled straight to the operating room, which has been the default pathway for this population.
Why now
Paper [0] shows that in cisplatin-ineligible muscle-invasive bladder cancer, perioperative enfortumab vedotin plus pembrolizumab started before surgery improved 2-year event-free survival from 39.4% to 74.7% (hazard ratio 0.40) and overall survival from 63.1% to 79.7% (hazard ratio 0.50), with surgery still completed in 87.6% of drug-treated patients vs 89.7% of controls — evidence that the neoadjuvant cycles do not derail the operation. Until now there was no accepted pre-surgery therapy for cisplatin-ineligible patients, so urology workflows had no reason to systematically identify them early; the trial creates that reason, and a simple eligibility-and-referral flag is the lowest-friction product to capture it.
Written by GLM · 12 Oct 2026
AI assessment
A high-impact, low-complexity clinical workflow tool that converts a breakthrough phase 3 trial result into a systematic standard of care by closing the gap between urology diagnosis and oncology referral.
- Evidence strength 5/5
- The idea is directly grounded in a phase 3 trial [1] showing a massive improvement in 2-year EFS (39.4% to 74.7%) specifically for the cisplatin-ineligible population, with clear eligibility criteria provided in supporting papers [2, 3].
- Market pull 5/5
- Health systems (Kaiser, Sutter) have a strong incentive to improve survival outcomes, and pharma partners (Astellas, Merck) have a direct commercial interest in ensuring eligible patients receive their specific drug combination.
- Novelty & moat 3/5
- While similar to a 'decision aid' in the catalog, this shifts the value from a patient-facing tablet to an EHR-integrated systemic trigger, which is a distinct and more scalable implementation.
- Feasibility 5/5
- The tool relies on existing EHR data (creatinine, problem lists, ECOG status) and standard referral workflows, making it a straightforward software integration rather than a new medical device.
- Wedge clarity 5/5
- The wedge is extremely sharp: identify cisplatin-ineligible patients at the moment of MIBC diagnosis to prevent the 'lost window' of neoadjuvant therapy.
- Simplicity / focus 5/5
- The product is a single, focused triage flag and referral trigger, avoiding the 'platform' trap by solving one specific clinical bottleneck.
Scored by Gemma 4 · 18 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.
Persona discussion
AI personas trained on real people's expertise debate this idea as it evolves.
View the discussion →Act on this idea
Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.
Business analysis
The PESTEL analysis reveals a high-potential opportunity driven by a breakthrough clinical shift in bladder cancer treatment, though success depends on overcoming EHR integration friction and high drug costs. The framework highlights a strong alignment between new clinical evidence and the need for systemic triage to prevent the loss of the critical neoadjuvant window.
Political2
Economic3
Social2
Technological2
Environmental1
Legal3
The success of this tool depends heavily on healthcare regulations, EHR integration capabilities, and clinical guideline adoption. · Generated 2026-10-18 by Gemma 4AI-generatedFull PESTEL Analysis →
Who benefits
- Kaiser Permanenteorganization
Integrated urology-oncology care for a large bladder cancer population; an automated ineligibility flag ensures members are routed to medical oncology before surgery is scheduled, protecting the neoadjuvant window.
- Astellas Pharmacompany
Enfortumab vedotin's benefit in [0] depends on therapy starting before cystectomy; systematic pre-surgical identification of cisplatin-ineligible patients protects that window and drives appropriate use.
- Sutter Healthorganization
A large health system whose community urology practices see these patients first; the flag operationalizes a new standard of care without adding clinician workload.
- Merck & Co.company
Pembrolizumab's perioperative benefit likewise requires pre-surgery initiation; the triage flag drives earlier medical oncology referral where the regimen can be offered.
- Society of Urologic Oncologyorganization
The professional society that educates the urologists who first diagnose these patients; the flag gives its members a concrete pathway to meet the new perioperative standard.
Research it builds on
- Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder CancerChristof Vulsteke, Nabil Adra, Pongwut Danchaivijitr et al. · 2026 · 113 citationsAll ideas from this paper →
- Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from the total KEYNOTE-052 study population.Arjun Vasant Balar, Daniel Castellano, Peter H. O’Donnell et al. · 2017 · 58 citationsAll ideas from this paper →
- Phase II neoadjuvant (N-) gemcitabine (G) and pembrolizumab (P) for locally advanced urothelial cancer (laUC): Interim results from the cisplatin (C)-ineligible cohort of GU14-188.Hristos Z. Kaimakliotis, Nabil Adra, William Kevin Kelly et al. · 2020 · 43 citationsAll ideas from this paper →
- Selection of Patients may Limit the Generalizability of Results from Cancer TrialsSophie D. Fosså, Eva Skovlund · 2002 · 38 citationsAll ideas from this paper →
- Cost-effectiveness analysis of perioperative durvalumab plus platin-based chemotherapy in muscle invasive bladder cancer in GermanyConstantin Rieger, Jörg Schlüchtermann, Julian Heidenreich et al. · 2025 · 3 citationsAll ideas from this paper →